Development of CP-506: A second-generation hypoxia-activated prodrug
題目：Development of CP-506: A second-generation hypoxia-activated prodrug
Associate Professor Adam Patterson is a leader of the ‘Targeting Tumour Hypoxia and the Vasculature to Treat Cancer’ flagship research programme.
Associate Professor Patterson is head of the Translational Therapeutics Team at the Auckland Cancer Society Research Centre. He has a broad interest in exploiting the tumour microenvironment as a therapeutic target, including both small molecules and biological agent based platforms. He is co-inventor of tarloxotinib (TH-4000), a first in class hypoxia-activated tyrosine kinase inhibitor currently in Phase 2 clinical trials.
Associate Professor Patterson obtained his degree in Biochemistry from the University of Oxford, before completing a PhD jointly at the Institute of Molecular Medicine (John Radcliffe Hospital, Oxford) and the MRC Radiobiology Unit (Harwell, Oxford). He is also a scientific consultant to Threshold Pharmaceuticals Inc., a biopharmaceutical company headquartered in San Francisco, California.